Incyte Past Earnings Performance
Past criteria checks 2/6
Incyte has been growing earnings at an average annual rate of 12.5%, while the Biotechs industry saw earnings growing at 15.2% annually. Revenues have been growing at an average rate of 12.1% per year. Incyte's return on equity is 0.6%, and it has net margins of 0.5%.
Key information
12.47%
Earnings growth rate
12.53%
EPS growth rate
| Biotechs Industry Growth | 17.04% |
| Revenue growth rate | 12.07% |
| Return on equity | 0.58% |
| Net Margin | 0.48% |
| Last Earnings Update | 31 Mar 2025 |
Recent past performance updates
Recent updates
Investors Aren't Buying Incyte Corporation's (NASDAQ:INCY) Revenues
Apr 30
Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib
Mar 18Incyte: Q4 Earnings Outlines Multiple Drug Launches In 2025
Feb 11Incyte: Multiple Drug Launches Bode Well For Future Growth
Jan 11Incyte: Q3 Earnings Ramping Up Growth To Jump The Patent Cliff
Oct 31
Tactical Expansions And First-in-Class Molecules Set To Propel Growth In High-Need Medical Areas
Incyte's focus on expanding its clinical pipeline with first-in-class molecules and novel therapies aims to drive growth by increasing market share and revenue.Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data
Aug 19Incyte: The Worst Has Been Avoided
Jun 16It's Probably Less Likely That Incyte Corporation's (NASDAQ:INCY) CEO Will See A Huge Pay Rise This Year
Jun 06Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)
Apr 26Incyte: A Potential GARP Superstar
Feb 27Revenue & Expenses Breakdown
How Incyte makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 25 | 4,413 | 21 | 1,264 | 161 |
| 31 Dec 24 | 4,241 | 33 | 1,239 | 161 |
| 30 Sep 24 | 4,076 | 32 | 1,207 | 164 |
| 30 Jun 24 | 3,857 | 97 | 1,165 | 164 |
| 31 Mar 24 | 3,768 | 745 | 1,143 | 164 |
| 31 Dec 23 | 3,696 | 598 | 1,159 | 127 |
| 30 Sep 23 | 3,609 | 425 | 1,138 | 0 |
| 30 Jun 23 | 3,513 | 366 | 1,136 | 0 |
| 31 Mar 23 | 3,470 | 324 | 1,105 | 0 |
| 31 Dec 22 | 3,395 | 341 | 999 | 113 |
| 30 Sep 22 | 3,331 | 876 | 954 | 0 |
| 30 Jun 22 | 3,320 | 945 | 879 | 0 |
| 31 Mar 22 | 3,115 | 933 | 796 | 0 |
| 31 Dec 21 | 2,986 | 949 | 741 | 0 |
| 30 Sep 21 | 2,913 | 535 | 682 | 0 |
| 30 Jun 21 | 2,721 | 338 | 612 | 0 |
| 31 Mar 21 | 2,703 | 478 | 561 | 0 |
| 31 Dec 20 | 2,667 | -296 | 518 | 0 |
| 30 Sep 20 | 2,457 | -335 | 487 | 0 |
| 30 Jun 20 | 2,388 | -191 | 469 | 0 |
| 31 Mar 20 | 2,229 | -376 | 457 | 0 |
| 31 Dec 19 | 2,159 | 447 | 469 | 0 |
| 30 Sep 19 | 2,108 | 405 | 441 | 0 |
| 30 Jun 19 | 2,006 | 306 | 435 | 0 |
| 31 Mar 19 | 1,997 | 253 | 437 | 0 |
| 31 Dec 18 | 1,882 | 109 | 435 | 0 |
| 30 Sep 18 | 1,798 | -109 | 424 | 0 |
| 30 Jun 18 | 1,729 | -102 | 419 | 0 |
| 31 Mar 18 | 1,534 | -167 | 401 | 0 |
| 31 Dec 17 | 1,536 | -313 | 367 | 0 |
| 30 Sep 17 | 1,419 | -155 | 363 | 0 |
| 30 Jun 17 | 1,306 | -154 | 348 | 0 |
| 31 Mar 17 | 1,226 | -107 | 324 | 0 |
| 31 Dec 16 | 1,106 | 104 | 302 | 0 |
| 30 Sep 16 | 1,023 | 151 | 260 | 0 |
| 30 Jun 16 | 941 | 74 | 231 | 0 |
| 31 Mar 16 | 858 | 49 | 216 | 0 |
| 31 Dec 15 | 754 | 7 | 197 | 0 |
| 30 Sep 15 | 634 | -86 | 193 | 0 |
| 30 Jun 15 | 644 | 13 | 184 | 0 |
| 31 Mar 15 | 581 | -33 | 174 | 0 |
| 31 Dec 14 | 511 | -48 | 166 | 0 |
| 30 Sep 14 | 485 | -54 | 155 | 0 |
| 30 Jun 14 | 372 | -136 | 142 | 0 |
Quality Earnings: INCY has high quality earnings.
Growing Profit Margin: INCY's current net profit margins (0.5%) are lower than last year (19.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: INCY has become profitable over the past 5 years, growing earnings by 12.5% per year.
Accelerating Growth: INCY's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: INCY had negative earnings growth (-97.1%) over the past year, making it difficult to compare to the Biotechs industry average (21.7%).
Return on Equity
High ROE: INCY's Return on Equity (0.6%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/27 17:01 |
| End of Day Share Price | 2025/05/27 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Incyte Corporation is covered by 53 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Thomas Russo | Baird |
| Ishan Majumdar | Baptista Research |